HCM
Price
$17.93
Change
+$1.56 (+9.53%)
Updated
Sep 12 closing price
Capitalization
2.78B
62 days until earnings call
TLRY
Price
$1.12
Change
+$0.06 (+5.66%)
Updated
Sep 12 closing price
Capitalization
1.25B
19 days until earnings call
Interact to see
Advertisement

HCM vs TLRY

Header iconHCM vs TLRY Comparison
Open Charts HCM vs TLRYBanner chart's image
HUTCHMED (China)
Price$17.93
Change+$1.56 (+9.53%)
Volume$92.78K
Capitalization2.78B
Tilray Brands
Price$1.12
Change+$0.06 (+5.66%)
Volume$46.75M
Capitalization1.25B
HCM vs TLRY Comparison Chart in %
Loading...
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HCM vs. TLRY commentary
Sep 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCM is a StrongBuy and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 13, 2025
Stock price -- (HCM: $17.93 vs. TLRY: $1.12)
Brand notoriety: HCM: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HCM: 179% vs. TLRY: 71%
Market capitalization -- HCM: $2.78B vs. TLRY: $1.25B
HCM [@Pharmaceuticals: Generic] is valued at $2.78B. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $1.25B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $65.68B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HCM’s FA Score shows that 1 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • HCM’s FA Score: 1 green, 4 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, HCM is a better buy in the long-term than TLRY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HCM’s TA Score shows that 5 TA indicator(s) are bullish while TLRY’s TA Score has 3 bullish TA indicator(s).

  • HCM’s TA Score: 5 bullish, 5 bearish.
  • TLRY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, HCM is a better buy in the short-term than TLRY.

Price Growth

HCM (@Pharmaceuticals: Generic) experienced а +12.27% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was -5.88% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.26%. For the same industry, the average monthly price growth was +4.29%, and the average quarterly price growth was +53.41%.

Reported Earning Dates

HCM is expected to report earnings on Nov 14, 2025.

TLRY is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HCM($2.78B) has a higher market cap than TLRY($1.25B). HCM YTD gains are higher at: 24.427 vs. TLRY (-15.789). HCM has higher annual earnings (EBITDA): 38M vs. TLRY (-2.13B). HCM has more cash in the bank: 1.37B vs. TLRY (256M). HCM has less debt than TLRY: HCM (93.4M) vs TLRY (329M). TLRY has higher revenues than HCM: TLRY (821M) vs HCM (602M).
HCMTLRYHCM / TLRY
Capitalization2.78B1.25B222%
EBITDA38M-2.13B-2%
Gain YTD24.427-15.789-155%
P/E Ratio6.77N/A-
Revenue602M821M73%
Total Cash1.37B256M533%
Total Debt93.4M329M28%
FUNDAMENTALS RATINGS
HCM vs TLRY: Fundamental Ratings
HCM
TLRY
OUTLOOK RATING
1..100
5774
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1999
PRICE GROWTH RATING
1..100
5050
P/E GROWTH RATING
1..100
9894
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HCM's Valuation (50) in the Pharmaceuticals Major industry is in the same range as TLRY (50) in the Biotechnology industry. This means that HCM’s stock grew similarly to TLRY’s over the last 12 months.

HCM's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as TLRY (100) in the Biotechnology industry. This means that HCM’s stock grew similarly to TLRY’s over the last 12 months.

HCM's SMR Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for TLRY (99) in the Biotechnology industry. This means that HCM’s stock grew significantly faster than TLRY’s over the last 12 months.

HCM's Price Growth Rating (50) in the Pharmaceuticals Major industry is in the same range as TLRY (50) in the Biotechnology industry. This means that HCM’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's P/E Growth Rating (94) in the Biotechnology industry is in the same range as HCM (98) in the Pharmaceuticals Major industry. This means that TLRY’s stock grew similarly to HCM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HCMTLRY
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 18 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
STFGX131.72N/A
N/A
State Farm Growth
JDPAX16.90N/A
N/A
Janus Henderson Mid Cap Value A
CSSAX30.58N/A
N/A
Carillon Chartwell Small Cap A
LZCOX10.09N/A
N/A
Lazard US Small Cap Equity Select Open
AVALX52.73N/A
N/A
Aegis Value I

HCM and

Correlation & Price change

A.I.dvisor tells us that HCM and ACET have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HCM and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HCM
1D Price
Change %
HCM100%
+9.53%
ACET - HCM
29%
Poorly correlated
-8.14%
TLRY - HCM
27%
Poorly correlated
+5.66%
CGC - HCM
27%
Poorly correlated
-1.44%
SNDL - HCM
25%
Poorly correlated
+0.84%
IRWD - HCM
24%
Poorly correlated
+5.65%
More

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been closely correlated with SNDL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
+5.66%
SNDL - TLRY
76%
Closely correlated
+0.84%
CGC - TLRY
63%
Loosely correlated
-1.44%
OGI - TLRY
61%
Loosely correlated
N/A
CRON - TLRY
60%
Loosely correlated
-1.94%
ACB - TLRY
56%
Loosely correlated
-1.22%
More